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Abstract    
Background: Trial-based cost-utility analyses require health-related quality of life data that generate utility values 
in order to express health outcomes in terms of quality-adjusted life years (QALYs). Assessments of baseline 
health-related quality of life are problematic where trial participants are incapacitated or critically ill at the time 
of randomisation. This review aims to identify and critique methods for handling non-availability of baseline 
health-related quality of life data in trial-based cost-utility analyses within emergency and critical illness settings. 
Methods: A systematic literature review was conducted, following PRISMA guidelines, to identify trial-based 
cost-utility analyses of interventions within emergency and critical care settings. Databases searched include the 
NIHR Journals Library (1991 to July 2016), Cochrane Library (all years); National Health Service (NHS) 
Economic Evaluation Database (all years) and Ovid Medline/Embase (without time restriction). Strategies 
employed to handle non-availability of baseline health-related quality of life data in final QALY estimations were 
identified and critiqued.  
Results: A total of 4224 published reports were screened, 19 of which met the study inclusion criteria (mean trial 
size 1,670); 14 (74 %) from the UK, 4 (21%) from other European countries and 1 (5%) from India. Twelve 
studies (63%) were based in emergency departments and  7 (37%) in intensive care units. Only one study was 
able to elicit patient-reported health-related quality of life at baseline.  To overcome the lack of baseline data when 
estimating QALYs, 8 (42%) studies assigned a fixed utility weight corresponding to either death, an unconscious 
health state or a country-specific norm to patients at baseline, 4 (21%) ignored baseline utilities, 3 (16%) applied 
values from another study, 1 (5%) generated utility values via retrospective recall and 1 (5%) elicited utilities 
from experts. A preliminary exploration of these methods shows that incremental QALY estimation is unlikely to 
be biased if balanced trial allocation is achieved and subsequent collection of health-related quality of life data 
occurs at the earliest possible opportunity following commencement of treatment followed by adequate number 
of follow-up assessments. 
Conclusion: Trial-based cost-utility analyses within emergency and critical illness settings have applied different 
methods for QALY estimation, employing disparate assumptions about the health-related quality of life of patients 
at baseline. Where baseline measurement is not practical, measurement at the earliest opportunity following 
commencement of treatment should minimise bias in QALY estimation.  
Key points for decision makers: 
 employ appropriate randomisation strategy to ensure baseline comparability across treatment groups 
 initial assessment of health-related quality of life of patients at the earliest time possible post 
randomisation and 
  inclusion of a constant or imputed baseline value rather than ignoring it. 
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1. Introduction  
Economic evaluations are increasingly being conducted alongside phase III and phase IV randomised controlled 
trials of various interventions such as surgical procedures, drug treatments, diagnostic tests and behavioural 
interventions [1] . In the United Kingdom (UK), government agencies such as the National Institute for Health 
and Care Excellence (NICE) for England and Wales, the All Wales Medicines Strategy Group (AWMSG)  for 
Wales and the Scottish Medicines Consortium (SMC) for Scotland have established decision-making processes 
that draw heavily upon economic evidence collected within the context of randomised controlled trials, whilst its 
research funding bodies such as the National Institute for Health Research (NIHR) routinely request the inclusion 
of economic assessment methods within large-scale clinical trials [1],[2]. Similarly, economic evidence collected 
within the context of randomised trials is increasingly being used to inform the regulatory and reimbursement 
decisions of government agencies in other nations [3, 4]. Depending on the research question, trial-based 
economic evaluations can take the form of cost-consequence analyses,  cost-effectiveness analyses  or cost-utility 
analyses. Cost-utility analyses are particularly appealing to decision makers as they permit cost-effectiveness 
comparisons to be made using the quality-adjusted life year (QALY) metric for different health care interventions 
across disparate health conditions.  It is unsurprising therefore that cost-utility analysis using the QALY outcome 
measure (which combines length of life and health-related quality of life in a single measure of health 
consequence) remains the preferred evaluative method in the technology appraisal guidance of many government 
agencies [1],[2].  
To generate the QALYs needed to inform trial-based cost-utility analyses, data on survival and data on health-
related quality of life measured at baseline and subsequent follow-up time points are required for trial participants.  
Randomised controlled trials  conducted in emergency and critical care settings have used various multi-attribute 
utility instruments, including the EQ-5D [5], SF-6D [6] and Health Utilities Index-3 (HUI-3) [7], to reflect  
preferences for patient health states; these are normally converted into health utility values using established 
algorithms [8-10]. In critical care settings, the psychometric properties of the EQ-5D and the SF-12 (from which 
the SF-6D can be derived) were recently examined in two patient populations, namely patients diagnosed with 
acute respiratory distress syndrome  [11]  and survivors of out of hospital cardiac arrest [12]. The authors of both 
studies reported satisfactory performance of these instruments in the respective patient populations. However, 
asking patients to complete these measures around the time of recruitment (commonly taken as the baseline 
measurement) into  randomised controlled trials conducted within emergency and critical care settings can be 
problematic; patients are commonly incapacitated and unable to provide a self-assessment of their health status at 
or around the time of randomisation [13],[14]. Problems also arise because the event of interest is often acute in 
nature rather than pre-planned; the unknown timing makes it difficult to collect baseline data from participants 
during the occurrence of the event and at the point of recruitment into the trial. Alternative strategies used to 
collect patient-reported outcome data in clinical trials more broadly, such as researcher-administered interviews 
(face-to-face or, in the context of longer term follow-up by telephone), can also be problematic to implement when 
patients are critically ill for the same reasons. Even where trial participants are conscious, the nature of some 
health conditions (for example cardiac arrest and serious traumatic injury) around the time of randomisation can 
often raise ethical objections to collecting patient-reported outcome data.  Solutions adopted by previous trial-
based economic evaluations within emergency and critical illness settings have included delaying the time at 
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which health-related quality of life is assessed until patients are well enough to complete questionnaires [15],[16], 
[17] , asking patients to retrospectively recall [18] their pre-randomisation health state and use of proxies such as 
patients’ next of kin or health professionals [19]. The impact of this heterogeneity of method upon the findings of 
economic analyses is unclear. 
An early systematic review of the critical care literature conducted in 2002 provided evidence of the difficulty of 
conducting within-trial cost-utility analyses involving critically ill or injured patient populations [20]. Of the 29 
economic analyses identified in that review, none was a cost-utility analysis. This systematic review therefore 
aimed to identify and critique approaches to collection of health-related quality of life data and subsequent 
estimation of QALYs in the absence of directly and contemporaneously measured baseline values in trial-based 
cost-utility analyses of interventions within emergency and critical illness settings. To our knowledge this problem 
has not been addressed before and there is scope to develop recommendations for future best practice to inform 
health economics researchers in emergency or critical care. The paper is structured as follows: section 2 outlines 
the systematic review methods followed by presentation of the results in section 3. A critical appraisal of the 
methods identified in the review for dealing with lack of baseline health-related quality of life data when 
estimating QALYs is presented in section 4. The aim is to understand the implications of the assumptions 
underlying each method and the likely impact on cost-effectiveness results. The discussion and conclusions are 
presented in section 5.   
 
2. Methods  
The NIHR Journals Library (1991 to July 2016), Cochrane Library (all years); National Health Service (NHS) 
Economic Evaluation Database (all years) and Ovid Medline/Embase (without time restriction) were searched. 
Search item groupings included terms and derivatives for “intensive care”, “economic evaluation” and 
“randomised controlled trial”. Full details of the search strategy are provided in Appendix A in the supplementary 
online material. 
Included studies were cost-utility analyses of interventions based in emergency or critical care settings, for 
example accident and emergency departments or intensive care units, which were conducted alongside 
randomised controlled trials. The randomisation (allocation to trial arm) had to be made whilst patients were in 
an emergency or critical care setting and consequently unable/incapacitated to provide self-assessment of their 
health status. Eligible studies had to have collected preference-based health-related quality of life data  from trial 
participants themselves, by proxy (e.g. relatives, healthcare professionals) or from an external source (for 
example, another study or expert opinion) to support the subsequent economic analysis. Studies were excluded if 
they did not include a cost-utility analysis or if the condition was non-acute, e.g. management of influenza, where 
patients could normally give written consent. In addition, because of the way disability-adjusted life years 
(DALYs) are calculated (i.e. the disutility weights are calculated for specific disease conditions and not based on 
patient preferences [21]), within-trial cost-utility analyses that reported outcomes in terms of DALYs were 
excluded. Mental health care related studies were excluded because of the particular methodological challenges 
presented. Non-English studies and the grey literature were also excluded. 
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Literature searches and reviews were performed in two stages in accordance with PRISMA guidelines [22]  and 
included studies published until July 2016.  First, titles and abstracts were screened to identify and retrieve 
potentially relevant reports. Second, retrieved full reports were assessed for eligibility. Both stages were 
completed independently by two reviewers (MD, FA) checking against pre-specified inclusion and exclusion 
criteria, with disagreements resolved through consensus. For eligible studies, data were extracted on the clinical 
setting, clinical condition, study perspective, time horizon, sample size, participant demographics, preference-
based health-related quality of life instrument(s), timing of data collection, source of (and where applicable 
accompanying assumptions around) baseline health-related quality of life data and methods used to estimate 
QALYs.  The quality of included studies was assessed using the strategy reported by Kendrick et al [23] and 
included the quality of the randomisation process, blinding of outcome assessment and completeness of follow-
up (see Appendix B in the supplementary online material for further details).  The review was registered on the 
PROSPERO register of systematic reviews (registration number CRD42016046174). 
 
Finally, the conduct and reporting of each trial-based economic evaluation was assessed against selected items on 
the CHEERS checklist [24] for reporting single study-based economic evaluations of interventions and expanded 
to include : i) study methods, including  description of target population, clinical settings, perspective of the 
analysis, study time horizon and whether or not cost and effects were discounted and if so by what amount; ii) 
method of data collection (including the type of preference-based health-related quality of life instrument used 
and the follow-up time points at which data collection was conducted); iii) method used to calculate QALYs, 
including, where applicable, how the non-availability of baseline health-related quality of life data was handled 
when estimating QALYs; iv) characterisation of uncertainty; and v) a critical and thematic appraisal of the 
reported methods used to handle non-availability of baseline health-related quality of life data in subsequent 
QALY estimation. Characterisation of uncertainty was assessed by examining whether studies reported parameter 
estimates together with associated measures of uncertainty (e.g. standard errors, confidence intervals, etc.) and 
investigated the impact of known methodological assumptions on final estimates of cost-effectiveness. Simple 
descriptive statistics were used to summarise characteristics of included studies and the methods used to handle 
non-availability of baseline health-related quality of life data in the cost-utility analyses. Results are presented 
narratively in textual format, providing numbers and corresponding percentages in brackets where appropriate.    
3. Results 
3.1 Summary of RCTs included in the review 
A total of 4224 published reports (e.g. published papers, book chapters, monographs, etc.) were screened (Figure 
1), of which 4113 were excluded after initial review of titles and abstracts. Of the remaining 111 full reports 
retrieved, 92 (83%) were excluded: 35 reported no economic evaluation outcomes at all (i.e. did not report cost-
effectiveness, cost-consequence or cost-utility outcomes), 16 reported economic evaluation outcomes that were 
not cost-utility based (i.e. were either cost-consequence or cost-effectiveness analyses in which the measures of 
health outcomes were not synthesised into preference-based metrics), 13 were conducted in non-emergency or 
critical care settings, 12 were duplicate reports, 15 were protocol papers and 1 study expressed the health outcomes 
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of the economic evaluation in DALY terms. A list of all 111 reports that reached the second stage of the review 
process is provided in Appendix C in the supplementary online material. 
Table 1 summarises the baseline characteristics of the 19 trial-based cost-utility analyses included in the review, 
published between 2004 and 2016.  The majority of studies, 14 (74 %), were conducted in the UK, 4 (21 %) in 
other European countries (namely Demark, Norway, Germany and Netherlands/Switzerland) and 1 (5%) in India. 
The mean number of patients in the underpinning randomised controlled trials was 1760 (range 180 to 6182), 
mean age was 53 years (range of means: 0.51 to 78) and mean percentage of males was 57% (range: 30% to 76%). 
In terms of clinical setting, 12 (63%) studies were based in emergency departments and included conditions such 
as emergency resuscitation for out-of-hospital cardiac arrest or acute asthma in adults and children and 7 (37%) 
in intensive care units.   
 One study [27] did not report a time horizon for the economic evaluation. The mean time horizon for the within-
trial component of the economic evaluations in the remaining 18 studies was 8 months (median 9 months and 
range 1 to 12 months). Some studies extrapolated outcomes beyond the trial follow-up period using decision 
analytic modelling methods [25, 26, 28] with up to 60 months [25] and lifetime [15, 16, 28, 29] extrapolations 
beyond the study follow-up periods. Most economic evaluations were conducted from the perspective of the UK 
National Health Service (NHS) (n=4) or the NHS/Personal Social services (n=9) in accordance with NICE 
guidance for appraising health technologies [30]. One further UK study adopted a societal as well as an NHS 
perspective [30]. Of the 5 non-UK studies [18] [25, 27, 31, 32] included in the review, 4  studies [18, 27, 31, 32] 
adopted a health services perspective, whilst one study adopted a third-payer perspective described as excluding 
costs to sectors other than the health sector and out-of-pocket expenses [25].  Most of the economic evaluations 
did not discount costs and effects in line with the relatively short time horizons of the within-trial analyses. Where 
studies had extrapolated cost and effects beyond the trial follow-up, discount rates of between 3.0% [25] and 3.5% 
[16, 28, 29, 33] per annum were applied to both costs and effects. In terms of study quality, all 19 (100%) studies 
reported using a randomisation process that was assessed as adequate according to the criteria described in 
Appendix B in the supplementary online material; 16 (84%) were un-blinded and 9 (47%) reported ≥80% 
completion rates for the primary outcome at end of follow-up. 
 
3.2 Measurement of health-related quality of life 
The most widely used generic preference-based health-related quality of life instruments include the EuroQoL 
EQ-5D [5] and the SF-6D [6] but other generic preference-based instruments such as the Health Utilities Index 
Mark 3 (HUI-3) [7] and the 15D-instrument [34] are also available for use.  
Table 2 presents a summary of the health-related quality of life data collection methods applied in the included 
studies and how non-availability of health-related quality of life data at baseline was handled in the QALY 
estimation. For the purpose of this review, we measured the baseline (or first) time point for describing  health-
related quality of life as reported by individual studies; conventionally in trial-based economic evaluations this is 
taken as the time of randomisation. Nine (47%) of the 19 studies used the EQ-5D to measure health-related quality 
of life of patients, 5 (26%) used the EQ-5D in combination with another instrument (primarily the SF-12/36 [26, 
33, 35], HUI-3 [32] and the paediatric PedsQL [36]), 1 (5%) [18] used the 15D instrument [34] and another 1  
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(5%) used the HUI-3 [28].  The remaining 3 (17%) studies [29] [25, 27]  did not report a primary health-related 
quality of life data collection process. Rather, the economic evaluations in these 3 studies were informed by utility 
data  extracted from external sources. In the study by Harvey and colleagues [29], age- and gender-specific utility 
values for the UK adult population were combined with survival estimates from the trial in order to estimate 
QALYs in the cost-utility analysis. Specifically, Harvey and colleagues "estimated the quality-adjusted life 
expectancy for each survivor at hospital discharge based upon the Office of National Statistics age and sex-specific 
life expectancy tables and the EQ-5D age- and sex-specific quality of life weights".  Gyrd-Hansen [25] and 
colleagues used 5 year QALY estimates for patients living with stroke obtained from the Oxford Stroke study [37]  
and stratified by stroke severity to inform the cost-utility analysis. Rosenthal et al  [27] applied a QALY reduction 
of 0.37 per day for patients in an intensive care unit, which they obtained for from a secondary study [38].  In 
addition, “…an extra decrement of 0.2 QALYs was assumed for patients at age 65 years, and an annual decrement 
of 0.005 [39] each year over 65 was considered as well”.  
 
3.3 Methods used to handle non-availability of baseline health-related quality of life in QALY estimation 
Only one [40] of the 16 studies that prospectively collected health-related quality of life data was able to do so at 
baseline (using date from 932 (86%) of the 1084 study participants). This study recruited patients with acute 
severe asthma from emergency departments. Patients had to be able to at least provide verbal consent and those 
with life threatening illness were excluded. EQ-5D data were collected at baseline by the recruiting physician.  In 
the remaining 15 studies, the earliest time point recorded for data collection directly from study participants varied 
from 2 days post-randomisation [41] to 12 months post-randomisation . The reported reasons for not assessing 
health-related quality of life at randomisation mostly reflected the condition of trial participants at this time point, 
concerns around utility measurement in these clinical settings, or reluctance to prioritise health-related quality of 
life assessment in studies with substantial data collection burden.  
The reported strategies used to handle the non-availability of health-related quality of life data at baseline in 
subsequent cost-utility analyses were available from 14 of the 15 studies that failed to collect baseline data and 
can be classified into four broad categories [note: the economic evaluation based on REAC-2 trial [32] data had 
not yet been published at the time of undertaking this review]: 
i) Eight (57%) studies assigned a fixed health utility value to all participants at baseline. This included 
assuming a zero value or a health state equivalent to death [33] [16] [17] or a utility value of -0.40 
reflecting an unconscious health state for the EQ-5D-3L [13] [26] [35]. One study [42] obtained 
baseline utility from an external source (i.e. the Health Survey of England) stratified by age and sex 
and another study [43] assumed equivalent baseline utility values across trial arms without reporting 
the actual values used.   
ii) Four (29%) studies [41] [15] [31]  [28] estimated QALYs using only the available data (i.e. from the 
first time point at which health-related quality of life was measured: 2 days post-randomisation in 
the study by Goodacre et al (2005) [41], 1 month post-randomisation in the study by Schuster et al 
(2015), 3 months post-randomisation in the study by Mouncey et al (2015) [15] and 1 year post-
randomisation in the subset of CHiP trial participants with traumatic brain injury [28]. This 
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effectively ignored the impact of interventions on participant’s health-related quality of life prior to 
these time points on final QALY calculations.  
iii) One (7%) study [18] asked patients to retrospectively recall at 14 days post-randomisation their pre-
randomisation health state.  
iv) Finally, one other  (7%) study [19] elicited external evidence on utility values associated with 
specific baseline health states using Delphi methods. The health status of participants measured at 
baseline was then translated/mapped onto EQ-5D-3L health states using evidence elicited from 
experts for incorporation in the final QALY calculations.     
3.4 Assessment of uncertainty around assumptions used to incorporate baseline utility in final QALY estimation 
Extensive sensitivity analyses were used by the included studies to investigate the impact that methodological 
assumptions (mostly around the inclusion of different cost variables reflecting alternative perspectives for the 
economic evaluation) had on incremental cost-utility estimates.  However, only one [19] of the 15 studies 
that did not collect baseline health-related quality of life data directly from patients (excluding the yet to be 
published analysis based on the REAC-2 trial [32]) specifically assessed the impact of the method and 
assumptions used to estimate baseline utilities on the cost-effectiveness results (Table 2).  In that particular 
study [19], varying the assumptions used to estimate baseline utilities had little impact on the final cost-
effectiveness results.  
4. Implications of methods for handling non-availability of baseline quality of life data 
4.1 Ignoring or assuming a fixed baseline utility value 
The selection of baseline health-related quality of life data in trial-based cost utility analyses is significant in two 
ways: first as an adjustment covariate within regression to estimate incremental costs and QALYs [44]; and second 
as the first point in an area-under-the-curve estimation of individual patient QALYs. 
The importance of the method of baseline health-related quality of life measurement is driven by the success of 
the trial randomisation in achieving a balanced allocation of individuals (in terms of patient characteristics) 
between treatment arms.  Baseline adjustment of health-related quality of life as a covariate within regression has 
become normal practice because of the need to manage the effect of baseline imbalances [44]. In the presence of 
baseline imbalances, different approaches to adjust for missing baseline health-related quality of life are likely to 
yield different answers.  In this circumstance, exploring alternative baseline proxy covariates may provide the 
best approach although trial stratification variables may adequately achieve this. As a general point, when 
estimating cost-effectiveness ratios with incremental QALYs close to zero, findings are likely to appear (perhaps 
artificially) sensitive to assumptions about baseline adjustment, since the incremental cost-effectiveness ratio 
(ICER) denominator may switch sign according to the approach taken. 
In terms of area-under-the-curve (AUC) calculations, in the presence of balanced allocation, incremental QALY 
estimation may be robustly estimated.  If it is assumed there is a true and variable unobserved baseline health-
related quality of life, then assuming a fixed value should not systematically bias the incremental QALY gain or 
cost-effectiveness estimation.  This is shown algebraically in Appendix D in the supplementary online material. 
In fact in the presence of imbalances, imposing a fixed baseline in the presence of an adequate number of multiple 
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follow-up valuations may only introduce limited bias as only the first of a series of measurements contributing to 
the area-under-the-curve is affected.  For example if QALY estimation is captured over a one year follow-up 
period and the first measurement is at 2 weeks then any baseline assumption will have a small effect on the overall 
incremental QALY gain. Ignoring the true baseline and starting from a delayed first measurement may introduce 
more significant bias since the area between the baseline and first measurement is lost.  Conversely, this bias 
would be exacerbated in the absence of an adequate number of multiple follow-up valuations. Algebraically the 
degree of bias is proportional to the magnitude of the time interval between randomisation and the first data 
collection point and the magnitude of the QALY gain between the two time intervals (Appendix E in the 
supplementary online material). Similarly, Figure 2 shows an example of a trial with a 12 month follow-up period 
where we assume no long term differences between treatment groups and a difference of 0.1 at the earliest follow-
up, time t. Assume time t is a trial design choice and can be varied. The error of taking the AUC from the earliest 
follow-up and not attempting a baseline estimate is minimal at 1 week and considerable at 6 months.  If an analyst 
does include a baseline assessment, then it doesn’t matter what baseline value is chosen between 0 and 1 (note 
utility values can take negative values in practice), AUC1 is the same regardless. Having a baseline assessment is 
increasingly important the more delayed the first measurement.  When there is imbalance at baseline, ignoring it 
and choosing a common baseline value will have a minimal effect for an early first measurement.  Suppose the 
baseline imbalance in health utility was 0.1 (the same as the treatment effect at time t).  Then the bias of missing 
the imbalance in the baseline model is similar to the error of not adjusting for baseline in a baseline balanced 
model.   
Consequently the eight studies that assigned a fixed baseline value should have produced unbiased estimates of 
incremental benefit in the absence of baseline imbalance; the three studies starting estimation from post-treatment 
would similarly be adequate if the duration between randomisation and the timing of the first measurement is a 
small proportion of the overall follow-up period.  In all circumstances the frequency of follow-up time points 
needs to be adequate to characterise the treatment effect, but has been simplified in Figure 2 for illustration.  
 
4.2 Retrospective recall of the baseline health-related quality of life data 
In the study by Bohmer and colleagues [18], “patients were carefully instructed to report health-related quality of 
life as it was experienced 14 days before the infarction (baseline value)”. The main appeal of retrospective recall 
is that baseline health-related quality of life data can be obtained from trial participants themselves. QALY 
estimates can also be adjusted to account for potential imbalances between groups [44]. The most obvious 
limitation is that it is not possible to obtain direct estimates from deceased or permanently incapacitated patients 
(who would not be missing at random). For example, in the PARAMEDIC 1 trial [35], only 6.6% of 1471 
individuals experiencing out-of-hospital cardiac arrest recruited into the trial survived to 3 months post arrest, the 
first time point at which health-related quality of life data were collected. Asking patients to retrospective recall 
their baseline health-related quality of life would not be an option for the majority of this trial’s participants.   
 
Another limitation of retrospective recall is the possibility of introducing recall bias in the final QALY estimation. 
The extent of any recall bias may depend on the clinical and demographic characteristics of patients and the length 
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of the recall period [45]; the longer this is, the more difficult it would be for patients to accurately recall and report 
on their baseline health-related quality of life. Wilson and colleagues [46] compared the use of retrospective recall 
of baseline health status versus population norms (New Zealand) in estimating change in health state valuations 
following acute-onset illness or injury. Their findings indicate a small but significant difference between pre- and 
post-injury health-related quality of life for people who had fully recovered, with recalled pre-injury health-related 
quality of life being higher than reported post-injury health. The reported health-related quality of life of the fully 
recovered patients was also higher than adult population norms. The authors concluded that “retrospective 
evaluation of health status is more appropriate than the application of population norms to estimate health status 
prior to acute-onset injury or illness, although there may be a small upward bias in such measurements.” Finally, 
provided that recall bias is similar in magnitude and direction across treatment arms, then it is unlikely to lead to 
a large effect on incremental QALYs.  
 
4.3 Eliciting external evidence and using mapping techniques to derive baseline health-related quality of life data  
Powell and colleagues [19] employed a more sophisticated technique to estimate baseline health-related quality 
of life based on a clinical outcome (Yung Asthma Severity Scores (ASS) in the context of acute severe asthma in 
children) measured at baseline. A physician panel comprising of two respiratory nurses and a consultant were 
asked to translate/map (not on the basis of a pre-existing association but rather their clinical opinion) ASS scores 
measured at baseline onto EQ-5D-3L health states from which baseline utility scores were estimated. More 
generally, ‘mapping’ techniques can be used to derive baseline health-related quality of life data if a condition-
specific outcome measure that is better able to reflect changes to health status of individuals can be collected at 
baseline and at subsequent follow-up time points when individuals are able to provide information on their health-
related quality of life. The relationship between the condition-specific outcome measure and the preference-based 
health-related quality of life measure can be derived using the data at follow-up time points when both outcome 
measures are collected. The mapping coefficients can then be used to derive baseline utility values based on 
responses to the condition-specific outcome measure at baseline.        
As with the management of non-availability of baseline health-related quality of life data, the choice of external 
utility values elicited from experts is unlikely to have a significant effect on incremental QALY estimation if 
balanced trial allocation is achieved, and may not introduce significant bias where baseline differences are small, 
or subsequent health-related quality of life measurement is adequately informative. 
 
5. Discussion 
Summary 
This review describes the conduct of cost-utility analyses alongside randomised controlled trials in emergency 
and critical care settings.  In this context, the estimation of QALYs is problematic because of difficulties in 
collecting health-related quality of life data from acutely ill or injured patients around the time of recruitment into 
trials. Four approaches for handling the lack of baseline health-related quality of life data in QALY calculations 
were identified among the 19 studies included in the review: a) assigning a fixed health state utility value (typically 
assumed to be zero, a utility value for an unconscious health state, or stratified by important predictors of health-
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related quality of life) to all patients at baseline; b) ignoring baseline health-related quality of life and estimating 
QALYs based on available data at later time points; c) retrospective recall of baseline health-related quality of 
life; and d) mapping from disease specific outcomes measured at baseline onto generic preference-based health-
related quality of life outcomes. The results suggest that there is no uniformity in approach amongst researchers 
conducting trial-based economic evaluations regarding the most appropriate strategy for dealing with the problem 
of non-availability of primary baseline health-related quality of life data when estimating QALYs to inform trial-
based cost-utility analyses within emergency and critical care settings. 
Some implications of the methods used for dealing with the lack of baseline health-related quality of life data 
have been explored. To permit robust trial-based cost-utility analysis, a critical factor is whether the treatment 
arms are balanced with respect to the health-related quality of life of patients at baseline. By definition this is not 
observed directly but may be implied by measured baseline differences in trial covariates. In this circumstance, 
proxy covariate adjustment of health-related quality of life estimates should be explored. In terms of area-under-
the curve QALY estimation, provided randomisation has resulted in balanced treatment groups at baseline and 
the first health-related quality of life assessment occurs early in the overall period of assessment (e.g. 2 weeks 
into a 52 week follow-up) then all methods are likely to give fairly similar answers, and estimated incremental 
QALYs will not vary significantly.  However, use of a fixed baseline may reconstruct treatment arm QALY gains 
more faithfully and may be preferable to simply starting QALY estimation from the first post-randomisation 
measurement: the fixed baseline health state utility value cancels out in the calculation of incremental QALYs 
(Appendix D in the supplementary online material).  In general, ignoring the baseline health-related quality of life 
measurement may increase potential biases, particularly if there is substantial delay to the first trial measurement 
point (Appendix E in the supplementary online material and Figure 2).  
 
A potential limitation of the review is the omission of studies that meet the inclusion criteria in the review process 
(either at the search or screening and selection stages of the review). This can occur where eligible studies fail to 
report sufficient details in titles and abstracts to enable them to be identified as trial-based economic evaluations. 
For example, where trials fail to find difference in effectiveness between comparator interventions, there may be 
insufficient interest to include health economic outcomes within the main trial report or publish separate cost-
effectiveness findings. The goal of the review was to characterise the types of approach used to compensate for 
unobtainable baseline utilities within the literature. Although some further eligible studies might have been 
obtained by more sensitive search methods, we have not identified any further approaches not already captured 
within this review. 
  
Recommendations for design of future trial-based economic evaluations in emergency and critical care settings  
o It is evident from the discussions above that an appropriate randomisation strategy should be employed 
to promote treatment groups that are similar in observable and unobservable patient characteristics. This 
in turn makes it likely that an unbiased estimate of incremental QALYs is produced irrespective of the 
strategy for dealing with the lack of baseline health-related quality of life data. It also limits the need for 
more complicated adjusted analyses to correct for the imbalances in baseline health utilities. It is 
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acknowledged that, as the outcome of randomisation is probabilistic, the best that randomisation can 
achieve is groups that are ‘similar’. It is thus possible that a perfectly valid strategy can still end up with 
a chance imbalance because there is a limit to the number of stratifying variables within randomisation, 
and blocking breaks down with low recruiting centres where these randomisation strategies are 
employed. 
o It is also evident that when possible, the initial assessment of health-related quality of life of patients 
should be conducted at the earliest time possible post randomisation. This might mean the initial 
assessment of health-related quality of life is conducted at different time points as and when each patient 
is able to complete the health-related quality of life questionnaire.  The differential times for the initial 
assessment would then be taken into account in the subsequent analyses. This is unlikely to cause 
problems if variation in first measurement time is random or small relative to the total follow-up. If, 
however, different treatments lead to substantially different durations to first measurement this might be 
an issue for incremental QALY estimation.  Further research should be considered to investigate whether 
or not collecting data at early time points offers advantages over data collection at a fixed time point for 
all patients.  
o Ignoring baseline utilities altogether in final QALY estimation is generally not preferable as this 
approach may result in biased estimates of incremental QALYs as demonstrated in section 4.1 and Figure 
2. 
o Identification and where possible collection of data on clinical variables (outcomes) that are strongly 
correlated with health-related quality of life and hence can be used to predict baseline health-related 
quality of life using mapping algorithms offers a route for further research enquiry.  
o In the context of data collection, if the incorporation of health-related quality of life data is considered 
burdensome by trialists, it is important that health economists provide clear methodological guidance on 
best methods that balance the need to minimise respondent burden against the requirement for 
minimising analytical biases. 
 
Concluding remarks 
Baseline health-related quality of life measurement is problematic in trial-based economic evaluations conducted 
in emergency and critical care settings. Consequently, trial-based cost-utility analyses have used different methods 
that make different assumptions about baseline health utilities.  Key messages that come out of this study include 
the need to employ appropriate randomisation strategies to ensure baseline comparability across treatment groups, 
initial assessment of health-related quality of life of patients at the earliest time possible post-randomisation and, 
where appropriate, inclusion of a constant or imputed baseline utility value rather than ignoring it. Further research 
is needed in order to determine the impact of different assumptions upon cost-effectiveness results, and to identify 
best methodological practice in this area. 
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Total=4224 
Full reports retrieved 
(n=111) 
Included in the review 
(n=19) 
Excluded 
Not an economic evaluation 
(n=35) 
Economic evaluation but not  a 
cost-utility analysis (n=16) 
Used DALYs (n=1) 
Not conducted in emergency or 
critical care (n=13) 
Duplicates (n=12) 
Protocol paper (n=15) 
Removed after screening 
of titles and abstracts 
(n=4113) 
NIHR library           
(n= 295) 
Cochrane   
(n=272) 
NHS EED 
(n=253) 
Medline 
(n=3404) 
  
Figure 1: Flow chart of study identification and selection 
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Figure 2: Effect of early measurement and baseline imbalance in health related quality of life on 
incremental QALY estimation using area-under-curve approaches. Health-related quality of life (utility) 
weight is displayed on the vertical axis and follow-up time on the horizontal axis. The left plot show the 
effect of early measurement and right plot the effect of baseline imbalance on incremental QALY 
estimation. Assuming that the maximum follow-up is12 months, there is no long term differences between 
treatment groups and that a difference of 0.1 at the earliest follow-up, time t. Assume further that t is a 
trial design choice and can be varied. Then error of taking the AUC from the earliest follow-up and not 
attempting a baseline estimate is minimal at 1 week and considerable at 6 months as shown in the box under 
left plot where AUC = AUC1+AUC2. Similarly, having a baseline assessment is increasingly important the 
more delayed the first measurement.  The right plot shows that when there is imbalance at baseline, 
ignoring it and choosing a common baseline value will have a minimal effect for an early first measurement 
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Table 1. Summary of trial-based cost-utility analyses included in the review 
First author (year), 
acronym 
Country Clinical 
setting 
Disease/condition Perspective Time 
horizon 
(months) 
Discounting 
costs and 
effects† 
Sample 
size 
Mean 
age 
(years) 
% 
male 
Goodacre (2005)[41] UK ED Acute, undifferentiated chest pain. NHS 6 No 972 50 64 
Harvey (2006)[29] UK ICU Critically ill patients in adult general 
intensive care. 
NHS/PSS 12a Yes, 3.5% 1041 65 58 
Dixon (2009)[43] UK ED Care of older people following a call for an 
emergency ambulance 
NHS/PSS 12 No 3018 78 43 
Peek (2010),  CESAR[33] UK ICU Severe adult respiratory failure. NHS, Societal 6 b  Yes, 3.5% 180 40 58 
Bohmer (2011)[18] Norway ED ST-elevation myocardial infarction Societal 12 No 266 61 76 
Goodacre (2011), 
3CPO[17] 
UK ICU Acute cardiogenic pulmonary oedema NHS/PSS 6a  Yes,3.5% 1069 78 43 
Goodacre (2011), 
RATRAC[16] 
UK ED Acute myocardial infarction. NHS 3 No 2243 55 58 
Lamb (2012), MINT[42] UK ED Acute whiplash injury NHS 12 No 3851 37 43 
Gates (2013), BALTI-2[13] UK ICU Acute respiratory distress syndrome NHS/PSS 12 No 326 55 65 
Powell (2013), 
MAGNETIC[47] 
UK ED Acute severe asthma in children NHS 1 No 508 4 58 
Goodacre (2014), 3Mg[40] UK ED Acute asthma in adults NHS/PSS 1 No 1084 36 30 
Macrae (2014), CHiP[28] UK ICU Blood glucose control in paediatric intensive 
care units  
NHS/PSS Life-time Yes,3.5%  1369 0.51c 55 
Gyrd-Hansen (2015), 
PHANTOM-S[25] 
Denmark ED Acute stroke Third-party1 3b Yes, 3.0% 6182 74 44 
Lall (2015),   OSCAR[26] UK ICU Acute respiratory distress syndrome NHS/PSS 12 No 795 55 62 
Mouncey (2015)[15] UK ED Early septic shock NHS/PSS 12a No 1260 65 56 
Perkins (2015), 
PARAMEDIC[35] 
UK ED Out of hospital cardiac arrest NHS /PSS 3 Unknown 4471 71 63 
Rosenthal (2015)[27] India ICU Nosocomial infections  Healthcare 
payer 
Not stated Not reported 1096 60 67 
Schuster (2015), IABP-
SHOCK II[31] 
Germany ED Acute myocardial infarction Healthcare 
(Germany) 
12 No 600 70c 69 
Sierink (2016) REACT-
2[32] 
Netherlands, 
Switzerland 
ED Trauma patients requiring advanced life 
support 
Healthcare  12 Unknown  1403 44 76 
aEtrapolated to lifetime; bExtrapolated to 60 months; cMedian age reported in original trial paper, Clinical settings (ED = Emergency department, ICU = Intensive care unit)  
†Discount rate per annum 
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Table 2: Summary of health-related quality of life measurement and assumptions around how baseline health-related quality of life information was incorporated 
into QALY estimation 
First author Instrument Data collection 
time points 
(months) 
Source of baseline health 
related quality of life data 
Methods used to estimate overall QALYs Was the impact of baseline utility 
values used on cost-effectiveness 
results investigated and or 
reported through sensitivity 
analyses? 
Goodacre 
(2004)[41] 
EQ-5D 0.07a, 1, 6 First time point data EQ-5D data over 6 months were combined with 
survival data to estimate QALYs using the area under 
the curve methods. 
No 
Harvey (2006)[29] None None UK ulation norms EQ-5D age- and sex-specific health-related quality of 
life weights for UK adult population combined with 
survival estimates from the trial 
Dixon (2009)[43] EQ-5D 1 Identical baseline scores 
assumed 
Incremental QALYs estimated assuming a linear 
change in EQ-5D scores and that the two groups have 
identical scores at baseline. 
No 
Peek (2010)[33] EQ-5D; SF-36 6 Zero score assumed  Linear interpolation No 
Bohmer (2011)[18] 15D instrument 0.5b,3,12 14 day retrospective recall Linear interpolation No 
Goodacre (2011), 
3CPO[17] 
EQ-5D 1, 3, 6 Zero score assumed Area under the curve  No 
Goodacre (2011), 
RATPAC[16] 
EQ-5D 1,3 Zero score assumed “Data are reported assuming that EQ-5D was zero at 
baseline, although means for any baseline score 
between 0 and 1 can be estimated by adding a 
constant k/24, where k is the baseline EQ-5D score of 
interest. As 3 months is approximately one-quarter of 
a year, the maximum possible number of QALYs 
accrued is 0.25 (assuming EQ-5D was 1 at baseline).” 
No 
Lamb (2012)[42] EQ-5D 0.5,4,8,12 UK pop norm assumed Baseline utility were taken from Health Survey for 
England and matched on age. 
No 
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Gates (2013)[13] EQ-5D 6,12 Unconscious (–0.402)  An unconscious patient (–0.402) for the baseline 
utility 
No 
Powell (2013)[47] Proxy EQ-5D, 
PedsQL 
1 Delphi exercise followed by 
mapping 
“A physician panel made up of two respiratory nurses 
and a consultant mapped the Yung Asthma Severity 
Score (ASS) scores on to EQ-5D health states from 
which baseline utility scores were estimated. In the 
base-case analysis, ASS scores of 1–3 were mapped 
on to an EQ-5D health state of 11111; ASS scores of 
4–6 were mapped on to an EQ-5D health state of 
22222; and ASS scores of 7–9 were mapped on to an 
EQ-5D health state of 33333.” 
Yes. This study reported varying 
the mapping algorithms used to 
estimate baseline utility as part 
sensitivity analyses. The results 
showed different assumptions about 
baseline utility values had little 
impact on the cost-effectiveness 
results (see page 55 of the HTA 
report).  
Goodacre 
(2014)[40] 
EQ-5D 0,1 Baseline data collected Not reported. Not applicable as study collected 
self-reported health-related quality 
of life data at baseline. 
Macrae (2014)[28] HUI-3 12 First time point 
Health-related quality of life was collected from a 
subset of patients who had traumatic brain injury at 
12 months from intensive care unit admission. The 
health-related quality of non-traumatic brain injury 
patients alive at 12 months post ICU admission was 
not assessed. Instead patients in this subgroup were 
assigned utility weights from another study.  QALYs 
were then derived by applying the utility weights 
each life-year of lived predicted for trial participants 
from 12 months post ICU admission. Patients who 
died before the 12 months period were assigned zero 
QALYs.  
No 
Gyrd-Hansen 
(2015)[25] 
None None External source QALY estimates from external source (Oxford 
Vascular study) were stratified by stroke severity 
Lall (2015)[26] EQ-5D, SF-12 6,12 Unconscious state (-0.40) Area under the curve assuming unconscious state 
(utility of –0.40) at baseline. 
No 
Mouncey 
(2015)[15] 
EQ-5D 3,12 First time point data QALYs estimated by combining survival data with 
quality-of-life scores at 90 days 
No 
Perkins (2015)[35] EQ-5D, SF-12 3,12 unconscious (–0.402)  Cost-effectiveness analysis not yet published. 
Personal communication with the trial health 
economics team indicate that the analysis will assume 
Cost-effectiveness analyses and 
results not yet reported 
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an unconscious state at baseline by applying utility 
score of -0.402.    
Rosenthal 
(2015)[27] 
None None External source QALYs and QALY decrements were obtained from 
another study and assigned to individual patients 
stratified by age 
Schuster (2015), 
IABP-SHOCK 
II[31] 
EQ-5D 1,6,12 First time point Area under the curve, starting from the first time 
point at which data were collected. 
No 
Sierink (2016)[32] EQ-5D, HUI-3 3,6,12 Cost-effectiveness analyses 
and results not yet published 
Cost-effectiveness analyses and results not yet 
published 
Cost-effectiveness analyses and 
results not yet published 
aRetrospective recall at 14 days post randomisation  
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Appendix A: Search strategy 
 
Database searched Timespan Search Strategy 
NIHR Journals 
Library 
1991 to 
2016 
 “intensive care” “economic evaluation” 
“critical care” “economic evaluation” 
 
Cochrane All years #1 Medical subject heading (MeSH) descriptor Intensive Care 
explode all trees  
#2 MeSH descriptor Critical Care explode all trees  
#3 MeSH descriptor Intensive Care Units explode all trees  
#4 (“acute care” or “critical care” or “critically ill” or “critical 
illness”)  
#5 “high dependency care” or “high dependency unit”  
#6 high next dependency next unit*  
#7 “intensive care”  
#8 (ITU or ICU or CCU or CICU or CITU) 
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)  
#10 (“cost effective*” or “cost benefit*” or “cost analys*” or 
“cost utili*”) ti,ab,kw 
#11(cost* or economic* or pharmacoeconomic*):ti 
#12 (“health economic*” or “healthcare cost*” or “health care 
cost*” or “economic evaluation*”):ti,ab,kw 
#13 (economical):ti,ab 
#14 (#10 OR #11 OR #12 OR #13) 
#15 "randomized controlled trial":pt 
#16 "randomised controlled trial":pt  
#17 "controlled clinical trial":pt 
#18 randomized: ti,ab  
#19 placebo: ti,ab  
#20 randomly :ti,ab  
#21 trial :ti,ab  
#22 groups :ti,ab 
#23(#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22) 
#24(#9 AND #14 AND #23)  
NHS EED All years (intensive care*) AND (economic evaluation*) AND 
(randomised controlled trial*) 
(critical care*) AND (economic evaluation*) AND 
(randomised controlled trial*) 
(intensive care*) AND (economic evaluation*) AND 
(randomized controlled trial*) 
(critical care*) AND (economic evaluation*) AND 
(randomized controlled trial*)  
Ovid Medline/ 
Embase 
All years 1.Critical Care/ or Intensive Care/ 
2.exp Critical Care/ 
3.acute care.mp. 
4.exp Critical Care/ 
5.exp Critical Illness/ 
6.critical illness.mp. or Critical Illness/ 
7.Hospital Units/ or Intensive Care Units, Neonatal/ or "Health 
Services Needs and Demand"/ or Intensive Care Units/ or 
Nursing Staff, Hospital/ or Intensive Care/ or Middle Aged/ or 
Critical Care/ or Esophageal Neoplasms/ 
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8.Postoperative Care/ or Postoperative Complications/ or 
Intensive Care/ or "Length of Stay"/ or Intensive Care Units/ 
or Progressive Patient Care/ or Aged/ or Middle Aged/ or 
Hospital Units/ or Adult/ 
9.Adult/ or Middle Aged/ or Thiourea/ or Pest Control, 
Biological/ or Bacillus thuringiensis/ or Thiouracil/ or Acute 
Kidney Injury/ or Critical Care/ or Intensive Care Units/ or 
Aged/ 
10.Respiration, Artificial/ or Aged/ or Critical Illness/ or 
Nursing Staff, Hospital/ or Adult/ or Monitoring, Physiologic/ 
or Middle Aged/ or Cross Infection/ or Intensive Care Units/ 
or Intensive Care/ 
11.Chest Pain/ or Aged/ or Patient Admission/ or Prospective 
Studies/ or Middle Aged/ or Coronary Disease/ or Coronary 
Care Units/ or Adult/ or Myocardial Infarction/ or Intensive 
Care Units/ 
12.Postoperative Complications/ or Intensive Care Units, 
Pediatric/ or Heart Diseases/ or "Length of Stay"/ or 
Myocardial Infarction/ or Child, Preschool/ or Cardiac 
Surgical Procedures/ or Coronary Care Units/ or Heart 
Defects, Congenital/ or CICU.mp. 
13.CITU.mp. 
14.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 
15.exp Fibroblasts/ or exp "Costs and Cost Analysis"/ or exp 
"Neoplasms, Glandular and Epithelial"/ or exp HIV Infections/ 
or exp Endometrial Neoplasms/ or exp Psychotic Disorders/ or 
exp Ovarian Neoplasms/ or exp Adult/ or exp Cost-Benefit 
Analysis/ or exp Neoplasm Recurrence, Local/ 
16.cost benefit.mp. or Cost-Benefit Analysis/ 
17.exp "Costs and Cost Analysis"/ 
18.exp Quality-Adjusted Life Years/ or exp Cost-Benefit 
Analysis/ or exp Health Care Costs/ or exp "Quality of Life"/ 
or exp "Costs and Cost Analysis"/ 
19.exp Economics, Pharmaceutical/ 
20.exp Cost-Benefit Analysis/ or exp Health Services 
Research/ or exp Economics, Medical/ 
21.exp Health Care Costs/ 
Health Care Costs/ 
23.economic evaluation.mp. or exp Cost-Benefit Analysis/ 
24.economical.mp. 
25.15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
26.randomized controlled trial.mp. or exp Randomized 
Controlled Trial/ 
27.controlled clinical trial.mp. or exp Controlled Clinical 
Trial/ 
28.randomized controlled trials.mp. or exp Randomized 
Controlled Trial/ 
29.random allocation.mp. or Random Allocation/ 
30.double-blind method.mp. or exp Double-Blind Method/ 
31.single-blind method.mp. or exp Single-Blind Method/ 
32.clinical trial.mp. or exp Clinical Trial/ 
33.clinical trials.mp. or exp Clinical Trial/ 
34.Comparative Study/ 
35.prospective studies.mp. or exp Prospective Studies/ 
22 
 
36.follow up studies.mp. or exp Follow-Up Studies/ 
37.26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 
36 
38.14 and 25 and 37 
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Appendix B: Study quality assessment 
The quality of included studies was assessed using the following strategy reported in Kendrick et al (2012) 
(page 6):  
 
1. “Quality of randomisation was considered to be adequate when study authors mentioned the use of 
sealed opaque envelopes, automated computerised randomisation programmes, minimisation 
programmes or independent researchers using a computer generated list of random numbers. It was 
considered to be inadequate where randomisation was based on coin tossing or drawing from packs of 
cards. If insufficient data were provided to judge the adequacy of randomisation, it was categorised as 
unclear”.  
 
2. “Outcome assessment was considered to be blinded if authors stated this, and where it was not stated it 
was categorised as unclear.” 
 
3. The percentage follow-up in each arm was calculated from the number allocated and the number with 
follow-up data for the primary outcome (including patients who have died) if they were included in the 
primary analysis. Completion rates were considered adequate if follow-up rate in each arm was more 
than 80%. 
 
Results of study quality assessment are shown below: 
First author 
(year), acronym 
Primary outcome Follow-up rates for 
primary outcome 
Randomisation 
method 
Study quality1 
Arm 1 Arm 2 Arm 3 
Goodacre (2004) Proportion admitted 69.5% 69.6%  Block 
randomisation 
A=A,B=N,F=N 
Harvey (2006) Hospital mortality 97.3% 97.6%  Central 
randomisation by 
telephone 
A=A,B=N,F=Y 
Dixon (2009) - - -  Cluster 
randomisation 
A=A,B=N,F=U 
Peek (2010),  
CESAR 
Death or 
severe disability at 6 
months 
57.8% 35.6%  Central 
randomisation by 
telephone 
A=A,B=N,F=N 
Bohmer (2011) Composite of death, 
reinfarction, stroke, or 
new myocardial 
ischemia at 12 months. 
97.1% 95.7%  Permuted block 
randomization 
A=A,B=N,F=Y 
Goodacre (2011), 
3CPO 
30 days mortality 94.8% 93.9% 96.6% Central 
randomisation by 
telephone 
A=A,B=N,F=Y 
Goodacre (2011), 
RATRAC 
Proportion of patients 
successfully discharged 
home after ED 
assessment. 
99.4% 98.9%  Simple 
randomisation 
sequence 
A=A,B=N,F=Y 
Lamb (2012), 
MINT 
Neck Disability Index 
(NDI) 
71% 70%  Cluster 
randomisation 
A=A,B=N,F=N 
Gates (2013), 
BALTI-2 
28 days mortality 98.1% 95.7%  Central 
randomisation by 
telephone 
A=A,B=Y,F=N 
Powell (2013), 
MAGNETIC 
Asthma severity score 
after 60 minutes of 
treatment 
90% 94.5%  Block 
randomisation 
A=A,B=Y,F=Y 
Goodacre (2014) the proportion of 
patients admitted to 
hospital; and the 
patient’s visual 
98% 97% 98% blocked 
randomisation 
(block sizes of 
four or six), 
A=A,B=Y,F=Y 
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analogue scale (VAS) 
for breathlessness over 
2 hours after initiation 
of treatment. 
stratified by 
hospital, 
Macrae (2014) numbers of days alive 
and free of mechanical 
ventilation within 30 
days 
63% 61%  central 
computerised 
randomisation 
A=A,B=N,F=N 
Gyrd-Hansen 
(2015), 
PHANTOM-S 
Alarm-to-thrombolysis 
time 
8.2% 6.4%  Block 
randomisation 
A=A,B=N,F=N 
Lall (2015),   
OSCAR 
30 days mortality 100% 100%  Central 
randomisation by 
telephone 
A=A,B=N,F=Y 
Mouncey (2015) 90 days mortality 90% 90%  Central 
randomisation by 
telephone 
A=A,B=N,F=Y 
Perkins (2015), 
PARAMEDIC 
Survival at 
30 days following 
cardiac arrest 
100% 99.9%  Cluster 
randomisation 
A=A,B=N,F=U 
Rosenthal (2015) Rates of central linee 
associated bloodstream 
infection 
- -  Block 
randomisation 
A=A,B=N,F=U 
Schuster (2015), 
IABP-SHOCK II 
30 days mortality 100% 100%  Central 
randomisation 
A=A,B=N,F=Y 
Sierink (2016) 
REACT-2 
In-hospital mortality 77.1% 77.3%  -  A=U,B=N,F=N 
1Study quality (A=Adequate allocation concealment; B=Blinded outcome assessment; F=At least 80% participants 
followed up in each arm; U=Unclear; N=No; Y=Yes) 
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Appendix C: List of included and excluded studies 
 
First author Year Reference  Included / 
Reason for 
exclusion 
 
Goodacre 2004 Randomised controlled trial and economic evaluation of a chest pain 
observation unit compared with routine care. BMJ (Clinical research 
ed). 2004;328(7434):254 
Included 
Harvey 2006 An evaluation of the clinical and cost-effectiveness of pulmonary 
artery catheters in patient management in intensive care: a systematic 
review and a randomised controlled trial. Health technology 
assessment (Winchester, England). 2006;10(29):iii-iv, ix-xi, 1-133 
Included 
Dixon 2009 Is it cost effective to introduce paramedic practitioners for older 
people to the ambulance service? Results of a cluster randomised 
controlled trial. Emergency medicine journa : EMJ. 2009;26(6):446-
51 
Included 
Peek 2010 Randomised controlled trial and parallel economic evaluation of 
conventional ventilatory support versus extracorporeal membrane 
oxygenation for severe adult respiratory failure (CESAR). Health 
technology assessment (Winchester, England). 2010;14(35):1-46. 
Included 
Bohmer 2011 Health and cost consequences of early versus late invasive strategy 
after thrombolysis for acute myocardial infarction. European journal 
of cardiovascular prevention and rehabilitation: official journal of the 
European Society of Cardiology, Working Groups on Epidemiology 
& Prevention and Cardiac Rehabilitation and Exercise Physiology. 
2011;18(5):717-23. 
Included 
Goodacre 2011 The RATPAC (Randomised Assessment of Treatment using Panel 
Assay of Cardiac markers) trial: a randomised controlled trial of 
point-of-care cardiac markers in the emergency department. Health 
technology assessment (Winchester, England). 2011;15(23):iii-xi, 1-
102 
Included 
Goodacre 2011 Health utility and survival after hospital admission with acute 
cardiogenic pulmonary oedema. Emergency medicine journal: EMJ. 
2011;28(6):477-82 
Included 
Lamb 2012 Managing Injuries of the Neck Trial (MINT): a randomised 
controlled trial of treatments for whiplash injuries. Health technology 
assessment (Winchester, England). 2012;16(49):iii-iv, 1-141 
Included 
Gates 2013 Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, 
randomised, double-blind, placebo-controlled trial and economic 
evaluation of intravenous infusion of salbutamol versus placebo in 
patients with acute respiratory distress syndrome. Health technology 
assessment (Winchester, England). 2013;17(38):v-vi, 1-87. 
Included 
Powell 2013 MAGNEsium Trial In Children (MAGNETIC): a randomised, 
placebo-controlled trial and economic evaluation of nebulised 
magnesium sulphate in acute severe asthma in children. Health 
technology assessment (Winchester, England). 2013;17(45):v-vi, 1-
216 
Included 
Gyrd-
Hansen 
2015 Cost-effectiveness estimate of prehospital thrombolysis: results of 
the PHANTOM-S study. Neurology. 2015;84(11):1090-7. 
Included 
Lall 2015 A randomised controlled trial and cost-effectiveness analysis of high-
frequency oscillatory ventilation against conventional artificial 
ventilation for adults with acute respiratory distress syndrome. The 
OSCAR (OSCillation in ARDS) study. Health technology 
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Appendix D: Equivalence of assigning same baseline utility weight to treatment and control groups on 
incremental QALY estimation 
Let A0Y  A1Y  and A 2Y represent 3 measurements of health-related quality of life of individual  in treatment arm 
A at time points 0, 1 and 2, respectively, where measurements at time point 0 represents baseline 
(randomisation) and time point 2 equals 1 year post randomisation. Let 1l represent duration of the time interval 
between the baseline and second time point measurements and 2l  the corresponding value for the interval 
between the second and third (final) measurements. Using the area under the curve approach [1] the total QALY 
accrued over the 1 year follow-up period is given by: 
   0 1 1 1 2 2
2 2
A A A A
A
Y Y l Y Y l
QALY
 
                                                                           (1) 
 Using the same formulation as above, the corresponding QALY estimate in treatment group B is given by 
   0 1 1 1 2 2
2 2
B B B B
B
Y Y l Y Y l
QALY
 
                                                                           (2)   
The incremental QALYs between the two groups is  
1 B AQALY QALY QALY                                                                                           (3) 
       0 0 1 1 1 1 1 1 2 2 2 2
1
1
2
B A B A B A B AQALY Y Y l Y Y l Y Y l Y Y l                               (4) 
Setting the baseline health-related quality of life to be same for the treatment group A and B implies assumption 
0 0B AY Y and therefore: 
      1 1 1 1 1 2 2 2 2
1
1
2
B A B A B AQALY Y Y l Y Y l Y Y l                                                    (5) 
Hence it does not matter what value the baseline utility value takes as this cancels out in the final estimate of the 
incremental QALYs. 
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Appendix E: Bias associated with ignoring baseline utility weight on incremental QALY estimation 
For treatment A is 
 1 2 2
2
A A
A
Y Y l
QALY

  and for treatment B is 
 1 2 2
2
B B
B
Y Y l
QALY

          so that the 
incremental QALYs is given by:  
 
   1 2 2 1 2 2
1
2
2
B B A AQALY Y Y l Y Y l                                                                       (6) 
   1 1 2 2 2 2
1
2
2
B A B AQALY Y Y l Y Y l                                                                       (7) 
The bias associated with not incorporating baseline health-related quality of life in the final estimates of 
incremental QALYs is given by:
         1 1 1 1 1 2 2 2 2 1 1 2 2 2 2
1 1
1 2
2 2
B A B A B A B A B AQALY QALY Y Y l Y Y l Y Y l Y Y l Y Y l                 
 1 1 1
1
1 2
2
B AQALY QALY Y Y l                                                                                              (8) 
Equation (8) implies that the magnitude of the bias is proportional to the difference between estimates of health-
related quality of life at time point 1 and duration of the time interval 1l  (i.e. the time interval between the 
baseline measurement and first follow-up measurement.  
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